Table 2.

Comparison of lipid profile among the studied groups.

Lipid profile	Mean ± SD	ANOVA test and P value	Post hoc P value
LDL (mg/dl)			P1 < 0.001**
Valproate-treated patients	139.7 ± 14.6	Test = 294.19	P2 < 0.001**
Levatiracetam-treated patients	123.1 ± 8.5	P value < 0.001**	P3 < 0.001**
Multidrug-treated patients	151.3 ± 14.1		P4 < 0.001**
Controls	83.0 ± 12.5		P5 < 0.001**
			P6 < 0.001**
HDL (mg/dl)			P1 < 0.001**
Valproate-treated patients	30.1 ± 1.7	Test = 154.85	P2 = 0.30
Levatiracetam-treated patients	35.3 ± 1.8	P value < 0.001**	P3 < 0.001**
Multidrug-treated patients	30.5 ± 1.8		P4 < 0.001**
Controls	36.7 ± 2.4		P5 < 0.001**
			P6 < 0.001**
Cholesterol (mg/dl)			P1 < 0.001**
Valproate-treated patients	179.9 ± 16.5	Test = 212.95	P2 < 0.001**
Levatiracetam-treated patients	149.4 ± 23.6	P value < 0.001**	P3 < 0.001**
Multidrug-treated patients	193.5 ± 16.9		P4 < 0.001**
Controls	109.6 ± 16.1		P5 < 0.001**
			P6 < 0.001**
Triglyceride (mg/dl)			P1 < 0.001**
Valproate-treated patients	170.2 ± 10.8	Test = 354.40	P2 < 0.001**
Levatiracetam-treated patients	148.7 ± 9.6	P value < 0.001**	P3 < 0.001**
Multidrug-treated patients	244.6 ± 38.4		P4 < 0.001**
Controls	110.3 ± 14.9		P5 < 0.001**
			P6 < 0.001**

P1: valproate-treated patients versus levatiracetam-treated patients; P2: valproate-treated patients versus multidrug-treated patients; P3: valproate-treated patients versus controls. P4: levatiracetam-treated patients versus multidrug-treated patients; P5: levatiracetam-treated patients versus controls; P6: multidrug-treated patients versus controls.

**Highly significant difference.